healthcare-thumbnail.png

Chemotherapy Induced Neutropenia (CIN) market Research Report

Published: 2025 - January

Report Code: VMR-17743

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Chemotherapy Induced Neutropenia (CIN) Market Analysis

The Chemotherapy Induced Neutropenia (CIN) market refers to the pharmaceutical market focused on the prevention and treatment of neutropenia induced by chemotherapy. Neutropenia is a potentially life-threatening condition characterized by a low count of neutrophils, a type of white blood cell, resulting from chemotherapy treatment. CIN can lead to increased vulnerability to infections, hospitalizations, and extended treatment cycles. CIN treatments include granulocyte colony-stimulating factors (G-CSF) and other therapies aimed at stimulating the production of neutrophils or directly managing neutropenia symptoms.

Disruptive Impact and Opportunities:

The CIN market is poised for significant disruption through innovative drug development, particularly in targeted biologics and oral therapies. Emerging therapies such as ALRN-6924, EC-18, and Plinabulin are offering promising new mechanisms of action and improved outcomes for patients with CIN. Oral and subcutaneous formulations are transforming treatment regimens by improving patient compliance and simplifying administration. Advances in safety profiles, such as fewer side effects compared to older treatments, are increasing the market's appeal to both clinicians and patients. With chemotherapy regimens remaining a cornerstone of cancer treatment, the CIN market represents a substantial growth opportunity, especially in the emerging markets and with the increasing incidence of cancer.

Chemotherapy Induced Neutropenia (CIN) Market Segmentation: Emerging Drugs

  • ALRN-6924

  • EC-18

  • Plinabulin

Chemotherapy Induced Neutropenia (CIN) Market Segmentation: Marketed Drugs

  • Neupogen (Filgrastim)

  • Neulasta (pegfilgrastim)

Key Companies:

  • Amgen

  • Kyowa Hakko Kirin Co., Ltd.

  • Teva B.V.

  • G1 Therapeutics

  • Spectrum Pharmaceuticals

  • Enzychem Lifesciences Corporation

  • Aileron Therapeutics

  • Cellerant Therapeutics

  • Myelo therapeutics

  • Beyond Spring Pharmaceuticals

  • Evive Biotech

Chemotherapy Induced Neutropenia (CIN) Market Segmentation: By Type

  • Primary Chemotherapy Induced Neutropenia

    • Mild Neutropenia

    • Moderate Neutropenia

    • Severe Neutropenia

  • Secondary Chemotherapy Induced Neutropenia

    • Febrile Neutropenia

    • Neutropenic Sepsis

Chemotherapy Induced Neutropenia (CIN) Market Segmentation: By Administration Type

  • Injectable

    • Subcutaneous (SC)

    • Intravenous (IV)

  • Oral

  • Intranasal

  • Transdermal

What’s in It for You?

  • In-depth analysis of emerging drugs and therapies in the CIN market

  • Market dynamics, trends, and opportunities for innovation in CIN treatments

  • Competitive analysis of key companies shaping the future of the CIN market

  • Strategic insights into market positioning and investment opportunities

  • Comprehensive forecasts to support decision-making in oncology portfolio management

  1. Chemotherapy Induced Neutropenia Market - Executive Summary

    1. Introduction

    2. Objectives

    3. Key Findings

      1. Market Size 2025 & 2030: By Key Country (10MM)

      2. Global Market Size 2025 & 2030: By Key Segment

      3. Key Investments & Startup Analysis

    4. Research Methodology

  2. Understanding the Disease

    1. Disease Overview

    2. Classification

    3. Signs and Symptoms

    4. Risk Factors

    5. Causes

    6. Disease Biology & Digital Innovations

    7. Stages & Staging System

    8. Diagnostic Algorithm

    9. Current Treatment Practices & Algorithm

    10. Current Standard of Care and Treatment Gaps

    11. Patient Demographics and Treatment Pathways

  3. Guidelines

  4. Unmet Needs

  5. Epidemiology and Patient Population

    1. Epidemiology Key Findings

    2. Assumptions and Rationale: 10MM

    3. Epidemiology Scenario: 10MM

    4. U.S. Epidemiology Scenario

    5. EU-5 Epidemiology

      1. U.K. Epidemiology Scenario

      2. Germany Epidemiology Scenario

      3. France Epidemiology Scenario

      4. Italy Epidemiology Scenario

      5. Spain Epidemiology Scenario

    6. Japan Epidemiology Scenario

    7. China Epidemiology Scenario

    8. Australia Epidemiology Scenario

    9. India Epidemiology Scenario   

  6. Real-world Data & Real-world Evidence

  7. Drug Development Landscape

    1. Existing Key Drug Candidate Profiles/ Marketed Therapies

    2. Competitive Analysis and Differentiation

    3. Overview of Similar/Competing Drugs in Clinical Trials

    4. Future Trends and Emerging Drugs

  8. Regulatory Strategy and Potential Challenges

    1. Regulatory Pathways in Key Markets

    2. Anticipated Regulatory Hurdles and Mitigation Strategies

    3. Case Studies in Oncology Drug Regulation

    4. Impact of Potential Changes to Regulatory Framework

  9. Commercial Landscape

    1. Market Size & Growth Rates

    2. Key Approvals & Anticipated Loss of Exclusivity

    3. PESTLE & Porter’s Five Forces Analysis

    4. Market Shares, Positioning/Ranking

    5. Market Drivers

    6. Identification of Threats

    7. Digital Evolution in Commercialization

  10. Market Segmentation

  11. Pricing, Reimbursement, and Access

    1. Competitive Pricing Analysis

    2. Reimbursement Landscape and Challenges

    3. Strategies for Market Access and Equity

    4. Patient Spending/Expenditure Analysis

  12. Future Trends, Disruptions, and Opportunities

    1. Analysis of Emerging Trends

    2. Technological Impact

    3. Impact of Potential Market Disruptors

    4. Opportunities for Future Development and Expansion

    5. Considerations for Investment Opportunities

  13. Global Market Dynamics

    1. Regional Regulatory Disparities

    2. Cross-Border Partnership Strategies

    3. Global Supply Chain Dynamics

    4. Case Studies: Success and Failure in Global Markets

    5. Strategies for Global Expansion and Localization

  14. Company Profiles

 

 

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.